Cadila Healthcare said its subsidiary Zydus Healthcare Ltd has bought six brands from MSD Pharmaceuticals India Pvt. Ltd, the local arm of US-based Merck & Co. Inc., for distribution in the Indian market. The value of acquisition was not disclosed.
The brands—Deca-Durabolin, Durabolin, Sustanon, Multiload, Sicastat and Axeten—belong to therapeutic areas of men’s health, women’s health, wound management and cardiovascular diseases and had combined sales of Rs84 crore in 2015, Cadila Healthcare said in a stock exchange filing.
MSD Pharma has transferred distribution and commercialization rights and assigned trademarks of all the six brands to Zydus Healthcare for the India market, the statement said. The company has also got distribution rights of Deca-Durabolin and Durabolin for Nepal.
“We have a longstanding association with MSD in India. The brands with their strong equity are a perfect addition and complement our core business and brands. We look at this as a great opportunity to strengthen our core offerings to create value and growth,” Sharvil Patel, chairman of Zydus Healthcare was quoted as saying in the stock exchange filing.
On 17 November, Cadila Healthcare said it would transfer its India human formulations business to Zydus Healthcare Ltd on a slump sale basis for Rs69.3 crore.
As per the deal, the India human formulations business, including a manufacturing plant at GIDC, Ahmedabad and pharmaceutical technology centre in Ahmedabad, will be transferred to Zydus Healthcare, Cadila Healthcare had said.
Cadila Healthcare’s India human formulations business had turnover of Rs1,371.2 crore in 2015-16, accounting for 21% of the company’s total turnover.